Get the Facts

Chronic lung disease is overlooked as a significant medical challenge, leaving patients with few options if conventional treatment isn’t effective or stops working. Lung Health Institute developed cellular therapy and the Anti-Inflammatory Initiative™ (AI²™)  to address this unmet need.

Joint Commission Accreditation

The Lung Health Institute received national accreditation and certification as a top health care organization providing safe, high-quality care to our patients.

Joint Commission Accreditation™

The Lung Health Institute received national accreditation and certification as a top healthcare organization providing safe, high-quality care to our patients.

Safe and Effective

  • All of our clinics and providers have the mandatory required oversight from the Department of Health, Board of Medical Examiners and the Board of Nursing.
  • The Gold Seal of Approval® from The Joint Commission is a symbol of quality that reflects an organization’s commitment to providing safe and effective patient care. Formerly known as JCAHO, The Joint Commission (TJC) is the nation’s oldest and largest standards-setting and accrediting body in health care.
  • Patient safety and care is our number one priority. Under current FDA guidelines and regulations 10 and 1271.15, the Lung Health Institute complies with all necessary requirements for operation. Regenerative medicine is a growing field, and we continue to expect new regulations from the FDA. When the new regulations are passed, we are fully prepared to comply with any regulation changes.

Cell harvesting and sourcing

  • Cellular therapy is performed in a clinical outpatient setting over the course of two days. After the Lung Health Institute’s medical staff have determined that a patient is a candidate for treatment, he or she will be asked to fill out all of the required paperwork. A pulmonary function test will be performed, and the patient will go through the preparation process.
  • Following the insertion of an IV, the blood cells are harvested, processed and separated and then immediately returned to the patient’s body intravenously where they may promote healing. This process is also repeated on day two of the patient’s treatment program. This minimally invasive procedure has proven to be a viable option for many patients with chronic obstructive pulmonary disease (COPD). At the end of day two, the overseeing clinician will do a thorough evaluation of the patient’s treatment and prep him or her for follow-up care.
  • Biological components of cellular therapy: platelet-rich plasma-platelet concentrate, platelets, WBC’S (leukocytes), granulocytes (neutrophils), lymphocytes and monocytes